The efficacy of Hsp90 inhibition in JAK2/STAT-driven diseases such as myeloproliferative neoplasms has been previously demonstrated, but linked primarily to increased JAK2 degradation [38]. This evidence concerns the gene SOAT1 and myeloproliferative neoplasm.